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It has recently been shown that the majority of prostate cancers harbour a chromosomal rearrangement that fuses the gene for an
androgen-regulated prostate-specific serine protease, TMPRSS2, with a member of the ETS family of transcription factors, most
commonly ERG. These are among the most common genetic alterations in any human solid tumour. This knowledge may provide us
with clues to prostate carcinogenesis, and may lead to the development of important molecular-based biomarkers for patients with
localised prostate cancer. The most common variant is fusion between the 50-untranslated region of TMPRSS2 and the 30 region of
ERG. However, over 20 other fusion variants have now been described (involving over 10 different genes) and the number of variants
continues to grow. Fusion products can be identified by several techniques, including FISH, RT–PCR, and expression profiling using
exon arrays. The protein products associated with the fusion transcripts have not been characterised, and the phenotypic expression
of the various products of gene fusion on prostate cancer histology, or on the clinical course of cancer, are not yet understood.
Several early cohort studies suggest that the presence of the TMPRSS2:ERG fusion product is associated with relatively poor cancer-
specific survival. Studies that examine how individual variants and their associated phenotypes affect prostate cancer presentation and
progression are required.
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FUSION OF TMPRSS2 AND ETS TRANSCRIPTION
FACTOR GENES
In 2005, Tomlins et al identified and described a small number of
fusion transcripts, specific to prostate cancer, that were the
consequence of a chromosomal rearrangement involving two
genes. One gene, TMPRSS2 (androgen-regulated trans-membrane
protease, serine 2), encodes for a serine protease that is secreted
by prostate epithelial cells in response to androgen exposure (Afar
et al, 2001). TMPRSS2 was fused to either ERG or ETV1, two
members of the ETS family of oncogenes (Tomlins et al, 2005). It
had earlier been reported that the ERG gene was the most
commonly overexpressed proto-oncogene in prostate cancer
(present in about 72% of cases of prostate cancer) (Petrovics
et al, 2005), and Tomlins et al now proposed a mechanism to
explain the overexpression. In this landmark paper, they found
that both intra-chromosomal and inter-chromosomal genetic
rearrangements led to the creation of a fusion transcript called
TMPRSS2–ETS. ETS is a family of transcriptional activators and
inhibitors. Their activity is regulated by phosphorylation and
protein–protein interactions (Seth and Watson, 2005). ERG, ETV1,
ETV4, and ETV5 are members of the ETS family. The ERG gene is
located on chromosome 21q, ETV1 is located on chromosome 7p,
ETV4 on chromosome 17q, and ETV5 on chromosome 3q. Using a
novel and powerful bioinformatic technique, they first determined
that either ETV1 or ERG (but not both) was commonly over-
expressed in prostate cancer cells. Furthermore, overexpression
did not usually include all ERG exons – exons 4–7 were
overexpressed much more commonly than were exons 1 and 2.
This intriguing observation suggested to them that the gene had
somehow been broken – and by sequencing the cDNA products,
they confirmed that the 50 part of the ERG gene had been replaced
by the sequence derived from the TMPRSS2 gene. They were able
to verify the rearrangement at the DNA level with FISH techniques.
Using expression arrays derived from prostate cancer specimens,
they confirmed that one of the two ETS oncogenes was over-
expressed in 57% of 167 prostate cancers. They concluded by
showing that, in cells which carried either fusion product,
expression of the ERG oncogene sequences was under the control
of androgen. For example, VCaP cells, which harbour the fusion
product TMPRSS2:ERG, expressed ERG transcript at a level 2000-
fold greater than LNCAP cells, which do not harbour a fusion
product. Because TMPRSS2 is regulated in the prostate by
androgens, it was proposed that this gene rearrangement could
be a mechanism whereby the ETV1 or ERG oncogenes were
overexpressed, leading to prostate cancer.
The TMPRSS2 and ERG genes are about 3 megabases (mB) apart
on chromosome 21. In about two-thirds of cases, fusion is the
result of the deletion of the intervening DNA sequence, but fusion
may also occur by a more complex rearrangement, such as a
translocation (Yoshimoto et al, 2006; Tu et al, 2007). The most
common fusion is between the 50-untranslated region of TMPRSS2
and ERG (Perner et al, 2006; Yoshimoto et al, 2006; Tu et al, 2007;
Mehra et al, 2007b). The specific points of DNA breakage, and the
exons retained in the fusion product, differ between patients. Over
20 TMPRSS2:ERG variants have now been described (Tomlins et al,
2005, 2006; Clark et al, 2007; Liu et al, 2007). A nomenclature has
been proposed to describe the variant transcripts, on the basis
which exons of the genes are involved (Clark et al, 2007). Most Received 17 January 2008; revised 2 July 2008; accepted 9 July 2008
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exon 2 of TMPRSSR2, and exon 4 of ERG (although exons 2–5 may
be involved). The most commonly reported fusion transcript is
between exon 1 of TMPRSS2 and exon 4 of ERG (Clark et al, 2007).
This particular rearrangement is designated as T1/E4 according to
the nomenclature proposed by Clark et al (2007). This transcript
was originally described by Tomlins et al (2005), and in some
studies, accounts for up to 86% of all reported fusions (Wang et al,
2006). Most patients who have been included in clinical and
pathologic studies so far carry a variant involving these two genes
(Wang et al, 2006; Demichelis et al, 2007; Lapointe et al, 2007; Nam
et al, 2007b; Attard et al, 2008).
The number of genes and the variants involved in fusion
transcripts continues to grow. Recently, it was found that other
members of the ETS gene family (ETV4 and ETV5) are involved in
a small proportion of prostate cancer cases (Tomlins et al, 2006;
Helgeson et al, 2008). New partners have also been identified on
the 50 side of the translocation. Lapointe et al (2007) identified a
fusion product derived from a variant isoform of TMPRSS2, which
mapped 4kb upstream of the more common start site (Lapointe
et al, 2007). One in 10 of the 63 prostate cancer cases in their series
expressed this unique isoform. Tomlins et al (2007) and Helgeson
et al (2008) implicated other 50 fusion partners for ETV1, including
SLC5A3, HERV-K22q11.23, C15orf21, and HNRPA2B1. SLC5A3
appears to be capable of fusion to ETV5, as well as to ETV1, but
not to ERG (Tomlins et al, 2007; Helgeson et al, 2008). Hermans
et al (2008) identified two additional fusion partners of ETV4
(kallikrein 2 (KLK2) and calcium-activated nucleotidase 1
(CANT1)) (Hermans et al, 2008).
Considering the new reports, it appears that a member of the
ETS family is overexpressed in the majority of prostate cancers and
that there may be mechanisms for overexpression other than
through gene fusion. In the original paper by Petrovics et al (2005)
a high proportion of cancers overexpressed ERG, but the under-
lying genetic mechanism was not determined. Cai et al (2007)
reported that ETV1 was overexpressed in the majority of prostate
cancers, but that only the minority of these had evidence of a
translocation (Cai et al, 2007). Hermans et al (2006) studied 11
prostate cancer xenografts, some of which exhibited androgen-
dependent growth. In the androgen-dependent cases, the
TMPRSS2:ERG fusion transcript was present, and overexpression
of the ERG gene was associated with the expression of androgen
receptor and PSA. Some androgen-independent cancers were also
found to contain the TMPRSS2:ERG fusion transcript, but lacked
androgen receptor – it is believed that these tumours have passed
through an androgen-dependent phase. They also found two cases
of advanced androgen-independent prostate cancer in which other
members of the ETS family (specifically FlI-1 and ETV4) were
overexpressed due to a mechanism other than gene fusion. Of the
50 fusion partners identified by Tomlins et al (2007), three
(TMPRSS2, SLC5A3, and HERV-K22q11.23) appear to be andro-
gen-responsive and two (C15orf21 and HNRPA2B1) appear to
result in constitutive overexpression of ETV1 in the absence of
androgen stimulation. In the future, clinical studies should
distinguish the course of the disease in cases of cancer with
different fusion proteins and the response to androgen ablation
treatment.
CHARACTERISATION OF TMPRSS2ERG PROTEIN
The consequence of the most common gene fusion is to generate a
hybrid transcript that attaches the prostate-specific promoter
sequence of the TMPRSS2 gene to the ERG oncogene open reading
frame (ORF). The proteins sequences have been predicted from the
sequence of the fusion ORFs. Clark et al (2007) studied cDNAs
prepared from ERG mRNAs isolated from 26 prostate cancers.
They reported that of the 14 different fusion transcripts identified
from the cDNA sequence, 5 would be predicted to generate
premature stop codons and would be unlikely to encode for a
functional ERG protein. In most cases, no amino acid sequence
derived from TMPRSS2 is integrated in the hybrid ORF, and
therefore a fusion protein is not created. In the case of the T1/E2
TMPRSS2:ERG variant, the full-length ERG protein is translated;
the other fusion transcripts encode for a truncated protein (Clark
et al, 2007).
PREVALENCE OF FUSION PRODUCT AMONG
UNSELECTED PROSTATE CANCER CASES
The presence of a gene fusion product can be determined by
measuring the level of RNA expression using RT–PCR, by using
FISH (which probes for inappropriate juxtaposition of non-
adjacent sequences or the ‘break apart’ of a single gene to different
chromosome locations), or by observing imbalance in the
expression of individual exons using array technology. The
prevalence rate of fusions among cancer patients depends on the
assay used, the volume of the cancer, the number of cancer foci
studied, and the number of fusion variants included in the
screening panel. The question of prevalence is also complicated by
the observation that a single cancer may have different foci that
harbour rearrangements involving different genes, or no rearrang-
ment at all (Clark et al, 2007). The field is evolving, but on the
whole, these data suggest that 70% or more of all prostate cancers
harbour a fusion product (Hermans et al, 2006; Perner et al, 2006;
Soller et al, 2006; Rajput et al, 2007; Tu et al, 2007; Nam et al,
2007a); individual estimates vary from 15% (Demichelis et al,
2007) to 78% (Soller et al, 2006). As the number of variant species
continue to increase and as techniques for measuring them
become increasingly diverse and more sensitive, we are likely to
find that an even greater proportion of prostate cancer specimens
contain one or more fusion variants.
Prostate cancer is often a multifocal disease. Mehra et al (2007a)
examined gene fusion status within different tumour foci from 43
patients with multifocal cancers, embedded in a tissue microarray
(Mehra et al, 2007a). Of these patients, 70% had cancers that
exhibited a fusion product, but in many cases, different foci from
the same tumour carried different fusion products. Surprisingly,
70% of the cases with fusion were discordant for the specific fusion
products. When the largest focus of cancer from each patient was
identified, 83% of samples had a rearrangement. A similar result
was obtained by Barry et al (2007), who studied 32 cases of
multifocal prostate cancer. Of these cases, 41% exhibited hetero-
geneity (Barry et al, 2007). Recently, Clark et al (2007) also found
that different cancer foci from a single patient harboured different
fusion protiens. In some cases, both ERG and ETV1 were involved
in different foci of cancer from the same patient. Thus,
heterogeneity of TMPRSS2:ERG gene fusion suggest that the
different foci of cancer that arise within a multifocal prostate
cancer probably have different origins and represent different
malignant clones – this observation also implies that the clinical
interpretation of this biomarker is more complex than was
originally thought.
PATHOLOGICAL CHARACTERISTICS
Despite the lack of characterisation of the individual proteins, the
phenotypic features of the TMPRSS2:ERG-associated cancers, as a
class, have been described. Mosquera et al (2007) studied 120 cases
of prostate cancer with the fusion gene, identified from a total of
253 cases (Mosquera et al, 2007). Five histologic features were
associated with the presence of gene fusion: the presence of blue-
tinged mucin, a cribriform growth pattern, macronucleoli,
intraductal tumour spread, and signet-ring cell features – these
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prostate cancer – but neither Gleason grade nor stage was
significantly associated with the presence of the fusion gene.
Several other studies have compared the characteristic of prostate
cancers with and without gene fusion in terms of grade and stage,
and PSA level (Perner et al, 2006; Wang et al, 2006; Lapointe et al,
2007; Rajput et al, 2007; Tu et al, 2007). Results to date have been
inconsistent, but most studies suggest that the presence of the
fusion protein is not correlated with other markers of risk. Rajput
et al (2007) found that fusions were less common in low-grade
(Gleason 2) prostate cancers (1 of 17; 7%) than in moderate
grade (Gleason 3–5) cancers (35 of 86; 41%; P-value for
difference¼0.02). Wang et al (2006) suggested that the T2/E4
variant might be associated with more aggressive disease than
other fusion transcripts. This might be the case if the abundance of
the oncogene transcript varied between cells with different fusion
species, but this hypothesis is not confirmed. TMPRSS2:ERG-
associated cancers have also been evaluated from the point of view
of gene co-expression. Iljin et al have reviewed expression data
derived from 410 different prostate tissue samples. They found that
the most common gene that was co-expressed with ERG was
histone deacetylase 1 (HDAC 1) and that, in fact, all the ERG-
positive prostate cancers in that series were also strongly positive
for HDAC (Iljin et al, 2006). This observation suggested to them
that anti-HDAC therapies might have a potential therapeutic
application for this class of prostate tumours (Li et al, 2005).
CLINICAL SIGNIFICANCE OF TMPRSS2:ERG GENE
FUSION
To date, there are three clearly established prognostic factors for
men with localised prostate cancer: histologic grade (measured by
the Gleason scoring system, tumour stage, and PSA level at
diagnosis. Men with tumours of higher grade (Gleason 8–10),
stage (T3–T4), or PSA level (e.g., 420ngml
 1) experience
relatively high rates of progression to metastasis, when compared
with men with tumours of lower grade, local stage, or low PSA
level. A biomarker will be clinically useful if it allows one to select
treatments for individuals; that is if it helps identify subgroups of
patients who will, or who will not, benefit from a specific
treatment. A patient may not benefit from a treatment because
survival is excellent in the absence of treatment, or because the rate
of progression is high despite treatment.
In an early study, Petrovics et al (2005) found that ERG
sequences were overexpressed in prostate cancer cells relative to
adjacent benign prostate cells (at a level of twofold or greater) in
approximately 80% of prostate cancers. In this study, patients with
the highest level of expression in their cancer cells (relative to
benign tissues) had the best prognosis, and the difference in
survival between the groups was highly significant.
The clinical significance of the presence of the TMPRSS2:ERG
gene fusion product on prostate cancer presentation and progres-
sion is not fully understood, but studies to date suggest that this
may be a biomarker of risk. The results of the various studies are
inconsistent, possibly because different study designs, different
biomarkers, and different end points are used. In general, the case
series (Lapointe et al, 2007; Rajput et al, 2007; Tu et al, 2007;
Attard et al, 2008) and case–control studies (Perner et al, 2006;
Wang et al, 2006) did not identify a significant prognostic effect.
Using a case–control approach, Wang et al (2006) examined 119
patients for fusion status. They found a significant correlation with
tumour stage, but not with early recurrence. Lapointe et al (2007)
found modest correlations between stage and grade and the
presence of the fusion product, but the sample size was small
(n¼63 cases) and neither association was statistically significant.
In contrast to the early study of ERG gene expression by
Petrovics et al (2005), three recent cohort studies that evaluated
the presence of the fusion protein per se on patient outcome have
found the translocation to be an adverse prognostic factor. Two
of these studies included patients undergoing watchful waiting.
These authors sought to determine whether patients who do not
harbour a fusion product might be candidates for watchful waiting.
Currently, it is estimated that up to 30% prostate cancer patients
lack the fusion protein, and therefore the potential exists to
avoid the morbidity associated with anti-androgen therapy or with
surgery for a significant proportion of patients. However, it should
also be remembered that more than half of prostate cancer patients
have cancers that harbour a fusion product, and we expect that
many patients with clinically localised disease will be cured of
cancer by prostatectomy, even if the fusion product is present.
Demichelis et al (2007) followed 111 patients undergoing
watchful waiting for localised prostate cancer (Demichelis et al,
2007). Patients with the gene fusion had a 2.7-fold increase in
prostate cancer-specific mortality, when compared with patients
without fusion. However, 23% of 94 patients without the fusion
protein experienced metastatic prostate cancer after 12 years of
observation, when compared with 53% of 17 patients with fusion.
Although the difference was statistically significant (Po0.01), a
recurrence risk of 23% is not sufficiently low to endorse watchful
waiting as an alternative to surgery. In a similar study, Attard et al
(2008) studied 445 patients under watchful waiting. Fusion analysis
was conducted on prostate specimens embedded in a tissue
microarray using FISH. In this study, patients without the fusion
transcript had a good survival experience (90% survival at 10
years). Attard et al (2008) refined their study by sub-dividing
patients with fusion transcripts into three categories: (1) those with
retained 50 and 30 ERG DNA sequences; (2) those with one retained
copy of 30 ERG sequence but no retained 50 ERG sequence; and
(3) those with two copies of the retained 30 ERG sequence
(i.e., homozygous or duplicated) but no retained 50 ERG sequence.
The third group was noteworthy for its poor prognosis; after
8 years of follow-up, patients in this group were six times more
likely to die from prostate cancer than those with no
TMPRSS2:ERG gene fusion (hazard ratio¼6.1, 95% CI: 3.3–11.1,
Po0.0001). Only 25% of patients in this class were alive at 8 years.
The frequency of gene rearrangements in the Attard et al (2008)
study was 30%, when compared with only 15% in the study by
Demichelis et al (2007). It may be that the Demichelis group used a
less sensitive assay to screen for the presence of the fusion gene, or
that a number of variant transcripts went undetected, and that this
resulted in misclassification and attenuation of the true effect
(however, in a later study from the same group, the low prevalence
of rearrangements was confirmed). The patients in the Demichelis
study were from Sweden, and it is possible that the prevalence of
the fusion protein varies with ethnic group. It remains to be
proven that patients who lack fusion genes may be candidates for
watchful waiting. Future studies might benefit from including
additional markers of risk in the prognostic model, including
grade, stage, PSA level, ethnic group, and the presence of one or
more markers of genetic susceptibility, such as the recently defined
cluster of markers on chromosome 8q24 (Amundadottir et al,
2006; Yeager et al, 2007; Zheng et al, 2007).
In a prospective cohort study, Nam et al (2007b) examined the
effect of the most common fusion variant (T1/E4) on disease
recurrence (defined by a rising PSA level after surgery) among 165
patients who underwent surgery for localised prostate cancer (Nam
et al, 2007b). This particular gene fusion was present in 49% of
patients, and 26% of the patients developed biochemical disease
recurrence. Patients with fusion had a much higher rate of
recurrence (54% at 5 years) than those without fusion (8%). Fusion
status did not correlate with PSA, grade, or stage. After adjusting
for PSA, grade, and stage, the hazard ratio for recurrence was 8.5
(95% CI: 3.6–20.6, Po0.0001). This study implies that this
biomarker may be an independent prognostic factor of disease
recurrence. However, although all patients who die of prostate
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minority of patients with biochemical recurrence succumb to
prostate cancer. It is important that large studies of prostatectomy
patients be conducted with longer follow-up and that additional
end points include distal recurrence and prostate-specific mortal-
ity. The T1/E4 variant is the most common of TMPRSS2:ERG gene
fusions and is the best studied; it is not yet known if other variants
are associated with prostate cancer prognosis to the same extent.
Furthermore, it is not clear why the results of the three cohort
studies (which examined the presence of the fusion protein) had
results that differed dramatically from those of Petrovics et al
(2005) who examined the overexpression of ERG. Petrovics et al
measured overexpression in cancer tissues relative to benign pros-
tate, and it is possible that expression levels in the surrounding
stroma are clinically relevant as well. In an ideal study, one would
perform both assays on a single group of patients.
The TMPRSS2:ERG gene fusion is specific for prostate cancer,
and the ability to identify this DNA rearrangement could be used
as a screening test for prostate cancer in serum, prostatic fluid, or
in urine. One study has been conducted on DNA specimens
isolated from urine from men known to have prostate cancer with
a gene rearrangement (Hessels et al, 2007). The sensitivity of the
urine test was only 37% and the specificity was 93%. It is possible
that future assays will have comparatively better sensitivity or that
the presence of the fusion gene in urine could supplement a panel
of markers in a screening setting.
CONCLUSIONS
In conclusion, the discovery by Tomlins et al in 2005 of a frequent
genetic rearrangement in prostate cancers has changed our
conception about the role of chromosomal rearrangements in the
aetiologies of common solid tumours. In the short time since this
discovery, several authors have confirmed the importance of this
genetic fusion, and have expanded the class of fusion genes greatly.
It now appears that these are among the most frequent recurrent
rearrangements in cancer. The consequence of the various fusion
transcripts is the overexpression of a member of the ETS family
of oncogenes, initially under the control of androgen and the
androgen receptor, but androgen dependence may be lost in
advanced disease. It now appears that activation of this pathway
may be central to prostate carcinogenesis, but the clinical
implication of the various fusion products has not been worked
out. It is hoped that this discovery will quickly lead to treatments
tailored to patients in different risk classes, and possibly to a
screening test, and ultimately it is hoped that the ETS family
oncogenes will be molecular targets for novel therapies.
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